Pinealon vs Follistatin 315
Side-by-side comparison of key properties, dosing, and research.
Cognitive EnhancementAnti-Aging & Longevity
PinealonAnabolic & IGF
Follistatin 315- Summary
- Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation, designed to penetrate the blood-brain barrier and exert neuroprotective, neurogenic, and anti-aging effects by regulating pineal gland and brain cell function.
- Follistatin 315 is a splice variant isoform of follistatin produced by alternative mRNA processing. Unlike Follistatin 344 which is tethered to cell surfaces via heparan sulfate proteoglycans, FST-315 circulates freely in the bloodstream and has broader systemic distribution. It is the predominant circulating form and exerts systemic myostatin inhibition as well as FSH suppression, making it relevant to both muscle growth and reproductive endocrinology.
- Half-Life
- Short (peptides rapidly degraded), but epigenetic/gene regulatory effects persist
- ~3–5 hours (longer systemic circulation vs FST-344)
- Admin Route
- SubQ, Oral, Intranasal
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 5–10 mg (oral) or 50–100 mcg (SC)
- No established human dosing protocol
- Frequency
- Once daily for 10 days
- Research use only
- Key Benefits
- Neuroprotection against oxidative stress and hypoxia
- Promotes neuronal regeneration and repair
- Improves memory and cognitive function
- Enhances sleep quality via melatonin regulation
- Anti-aging effects on brain cells
- May slow cognitive decline in neurodegeneration
- Improves cerebrovascular circulation
- Reduces neuroinflammation
- Systemic myostatin inhibition for whole-body muscle growth
- Freely circulating — broader tissue distribution than FST-344
- Strong FSH-suppressive activity useful in certain hormonal protocols
- Potential for greater anabolic effect across multiple muscle groups simultaneously
- May be more relevant to reproductive endocrinology applications
- Studied in gene therapy approaches for muscular dystrophy
- Side Effects
- Excellent safety profile in clinical use
- Rare: mild drowsiness
- Transient mild headache at initiation
- Injection site reaction (SC)
- Systemic FSH suppression — significant concern for fertility
- Greater potential for off-target effects vs FST-344 due to systemic distribution
- Limited human safety data
- Potential cardiac hypertrophy with prolonged high-dose exposure
- Stacks With
- —
- —